ReviewPharmacoEconomics2017

Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Philip Morgan et al.PubMed ↗Publisher ↗

No numbers read from the abstract.